Illumina shareholders vote to install Carl Icahn board nominee, oust chair

Carl Icahn has accused Illumina's management and board of poor oversight, particularly with regard to the company's acquisition of cancer test maker Grail.

from Health and Science https://ift.tt/ItaXgJV
https://ift.tt/sENgyDk
https://ift.tt/z8knewI